Safety and immunogenicity of a candidate Middle East respiratory syndrome coronavirus viral-vectored vaccine: a dose-escalation, open-label, non-randomised, uncontrolled, phase 1 trial

Folegatti PM., Bittaye M., Flaxman A., Lopez FR., Bellamy D., Kupke A., Mair C., Makinson R., Sheridan J., Rohde C., Halwe S., Jeong Y., Park Y-S., Kim J-O., Song M., Boyd A., Tran N., Silman D., Poulton I., Datoo M., Marshall J., Themistocleous Y., Lawrie A., Roberts R., Berrie E., Becker S., Lambe T., Hill A., Ewer K., Gilbert S.

DOI

10.1016/s1473-3099(20)30160-2

Type

Journal article

Journal

The Lancet Infectious Diseases

Publisher

Elsevier BV

Publication Date

07/2020

Volume

20

Pages

816 - 826

Permalink Original publication